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Epithelial ovarian cancer is the most lethal gynecologic malig-
nancy; it is highly aggressive and causes almost 125,000 deaths
yearly. Despite advances in detection and cytotoxic therapies,
a low percentage of patients with advanced stage disease survive
5 y after the initial diagnosis. The high mortality of this disease is
mainly caused by resistance to the available therapies. Here, we
proﬁled microRNA (miR) expression in serous epithelial ovarian
carcinomas to assess the possibility of a miR signature associated
with chemoresistance. We analyzed tumor samples from 198
patients (86 patients as a training set and 112 patients as a
validation set) for human miRs. A signature of 23 miRs associated
with chemoresistance was generated by array analysis in the
training set. Quantitative RT-PCR in the validation set conﬁrmed
that three miRs (miR-484, -642, and -217) were able to predict
chemoresistance of these tumors. Additional analysis of miR-484
revealed that the sensitive phenotype is caused by a modulation
of tumor vasculature through the regulation of the VEGFB and
VEGFR2 pathways. We present compelling evidence that three
miRs can classify the response to chemotherapy of ovarian cancer
patients in a large multicenter cohort and that one of these three
miRs is involved in the control of tumor angiogenesis, indicating
an option in the treatment of these patients. Our results suggest,
in fact, that blockage of VEGF through the use of an anti-VEGFA
antibody may not be sufﬁcient to improve survival in ovarian can-
cer patients unless VEGFB signaling is also blocked.
Ovarian cancer is the leading cause of gynecological cancer-related death in the developed world (1). Although progress
has been made in its treatment by improved debulking surgery
and the introduction of platinum–taxane regimens (2), the
overall 5-y survival is only 29% in advanced stage disease (1),
mostly because of diagnosis at an advanced stage and intrinsic
and acquired resistance to platinum-based chemotherapy. Iden-
tifying molecular markers of ovarian cancer chemoresistance is,
therefore, of crucial importance. Successful translation of ﬁnd-
ings at the molecular level will lead to individualized treatment
regimens, improved chemotherapeutic response rates, and avoid-
ance of unnecessary treatments.
MicroRNAs (miRs) are a class of small noncoding RNAs that
modulate gene expression by causing translational repression,
mRNA cleavage, or destabilization (3). They are involved in nu-
merous physiological cellular processes (4–7). Most importantly,
accumulating evidence indicates that many miRs are aberrantly
expressed in human cancers (8–10), and their expression proﬁles
can classify stage, subtype, and prognosis of some cancers (11–14).
In this report, we describe an miR signature that deﬁnes
chemoresistant ovarian carcinoma. We show that some miRs are
deregulated in most patients with resistant ovarian carcinomas,
and we show that miR-484 exerts its action through the regula-
tion of angiogenic factors. We postulate that this miR signature
of drug resistance could be used to develop strategies for tar-
geted therapies in chemorefractive ovarian carcinoma patients.
Results
miR Expression in Serous Ovarian Carcinomas is Related to Chemoresis-
tance. To investigate whether miRs could predict serous ovarian
carcinoma (EOC) chemoresistance, we analyzed the expression
of 676 miRs in the training set (Table S1). As shown in Fig. 1A,
we were able to identify a response signature with 23 differen-
tially expressed miRs capable of discrimination among the four
different groups. Cluster analysis of the centroids (Fig. 1B)
revealed that the EOC samples can be grouped in two major
classes: complete and partial responders. Furthermore, they can
be labeled as responders on one side, and stable and progressive
disease, labeled nonresponders, is on the other side. Thus, we
used these two classes to further reﬁne the response signature
and deﬁne 12 miRs (Fig. 1C). We used 112 EOC samples from
a second patient cohort to validate the response miRs (Table S1).
Of 12 miRs initially identiﬁed, we were able to conﬁrm three miRs
down-regulated in nonresponder tumors: miR-484 (P value =
0.0007), miR-642 (P value = 0.041), and miR-217 (P value =
0.046) (Fig. 1D). We focused our attention for additional studies
on miR-484, which was the most statistically signiﬁcant.
miR-484 Expression Does Not Alter in Vitro Sensitivity to Carboplatin
and Taxol. To obtain insight into the role of miRs in the devel-
opment of drug resistance, the expression levels of miR-484 were
evaluated in six different epithelial ovarian carcinoma cell lines
(Fig. S1A). Surprisingly, treating the cells for 2 or 4 hwith increasing
concentrations of carboplatin (CBDCA) and taxol (Tax) showed
that their IC50 value was not related to the endogenous levels of
miR-484, which were evaluated 4 d later by 3-(4, 5-Dimethyl-2-
thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTS) assay (Fig.
S1B). Moreover, overexpression of miR-484 in both MDAH-2274
and SKOV-3 cell lines did not signiﬁcantly affect their in vitro
sensitivity to CBDCA and Tax (Fig. S1 C and D).
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Role of miR-484 in the Acquisition of Chemoresistance. Because
levels of miR-484 were similar among cell lines, we used MDAH-
2774 and SKOV-3 cells overexpressing either control miR (scr) or
miR-484 to create, in vivo, the responder phenotype and explore the
possibility that miRs inﬂuence the chemosensitivity of ovarian cancer
in a context-dependentmanner.miR-484was stably overexpressed in
both cell lines using a lentiviral vector also encoding the EGFP
protein to better follow tumor growth in vivo. Stably transducedmiR-
484 cells showed a 2.0- to 3.5-fold increase in the expression of the
miR compared with scr-transduced cells shown in Fig. 5A, differ-
ences similar to those differences observed in primary EOC between
responders and nonresponders tumors. In vitro studies using a ﬂuo-
rescence microscope showed that the EGFP ﬂuorescence was
scarcely detectable in MDAH-2774 cells (gray value: 750 ± 120
and 850 ± 230 for MDAH-2774 miR-484 and scr, respectively),
whereas it was very bright in SKOV-3 cells, with miR-484 cells
slightly brighter than scr-transduced cells (gray value: 5,450 ± 890
and 3,250 ± 630 for SKOV-3 miR-484 and scr, respectively). For
these reasons, only SKOV-3 cells were followed for their growth
using an in vivo imaging system able to detect the EGFP ﬂuo-
rescence, whereas the growth of MDAH-2774 miR-484 and scr-
transduced cells was followed using a caliper-based method.
Cells (1.5 × 106) were inoculated into nude mice s.c. into the
left (EGFP-miR-484-MDAH-2774) and right (EGFP-MDAH-
2774) ﬂanks and allowed to grow for 15 d. At this time, the tumor
volume formed by miR-484–expressing cells was not statistically
different from the one observed in control EGFP-expressing
cells (Fig. 2A, Left), indicating that the growth of the primary
tumor, at least in the ﬁrst phases of tumor development, was not
affected by the expression of the miR. After CBDCA and Tax
treatment, control tumors increased their size about sixfold
compared with day 0 at the end of the treatment (range = 2.3–
17.7). In the same mice, miR-484–expressing tumors increased
only 1.3-fold (range = 0.8–1.8), showing to be much more sen-
sitive to the drugs than the controls (Fig. 2A, Right). Using an
in vivo imaging system able to detect EGFP ﬂuorescence, the
analysis of SKOV-3 cells conﬁrmed that the expression of miR-
484 did not affect the growth of the primary tumor but signiﬁ-
cantly increased the sensitivity to treatment (Fig. 2 B and C).
The higher ﬂuorescence intensity of tumors expressing miR-484
in untreated mice (Fig. 2C, Left) was, in fact, expected, and it
reﬂected the higher EGFP ﬂuorescence intensity of miR-484-
SKOV-3 cells observed in vitro. We then used MDAH-2774
cells, which grew more rapidly in nude mice than SKOV-3 cells,
to examine whether in vivo administration of the miR could alter
the sensitivity of EOC to CBDCA+Tax treatment. Parental
MDAH-2774 cells were allowed to grow for 2 wk in the ﬂanks of
nude mice, and then, they were injected with lentivirus-expressing
EGFP-control miR in the right ﬂank and lentivirus-expressing
EGFP-miR-484 in the left ﬂank. Beginning 2 d later, mice were
treated biweekly for 3 wk with CBDCA+Tax, and the intra-
tumoral injection of virus was repeated after 1 wk. After 21 d,
tumor growth was evaluated. Strikingly, in six of six cases, miR-
484 increased drug sensitivity, showing that its expression is able
to modulate resistance to CDBCA and Tax in epithelial ovarian
cancer in vivo (Fig. 2D). To examine the tumor response, mouse
samples were stained with H&E, and apoptosis was evaluated by
TUNEL assay. Although no increase in apoptosis was observed,
it was noted that, in miR-484–transduced tumors, there was a
dramatic increase in necrosis. In fact, as shown in Fig. 2 E and F,
miR-484–transduced tumors showed 58.4% ± 17 (range = 27–
92), whereas scramble-transduced tumors showed 12% ± 17
(range = 0–65) of necrosis.
miR-484 Regulates the Expression of Angiogenic Factors. Our data
pointed to a role of miR-484 in the chemosensitivity of EOC
cells in vivo but not in vitro, suggesting that it might act on the
tumor microenvironment rather than in a cell autonomous
manner. Searching for putative targets, we found that miR-484
may be involved in the regulation of angiogenic factors. In fact,
miR-484, according to different prediction algorithms, targets
the VEGFB, which is able to directly stimulate endothelial cell
growth and migration (15), and the VEGFR2/KDR, which is
implicated in all aspects of normal and pathological vascular
endothelial cell biology (16). Luciferase and Western blot anal-
yses conﬁrmed that miR-484 overexpression down-regulated
the endogenous levels of VEGFB and VEGFR2 (Fig. 3). Thus,
we hypothesized that some modiﬁcations in the vascular asset
of responders and nonresponders in human and mouse tumors
might occur. Vascular density was assessed using an antibody
against anti-CD34, which is a single-chain transmembrane gly-
coprotein, associated with human hematopoietic progenitor
cells. We used 30 cases of human serous ovarian carcinoma (15
responders and 15 nonresponders) and 28 cases of mice xeno-
graft tumors [14 cases from SKOV-3 and 14 cases from MDAH-
2774 (7 cases transduced with miR-484 and 7 cases transduced
with EGFP)] and evaluated using the Chalkley eyepiece method
(17). In human tumors, the mean microvessel density was 30 ±
1.17 (range = 9–54) for responders and 68 ± 1.6 (range = 15–
114) for nonresponders (P = 0.0000002); in mice, it was 9 ± 5.5
(range = 1–18) for SKOV-3-miR-484, 23 ± 12 (range = 5–37)
for SKOV-3-EGFP (P = 0.0004), 10 ± 6.2 (range = 4–22) for
Fig. 1. miR signature classiﬁes responder vs. nonresponder ovarian cancer
patients. (A) Analysis of training set using TLDA cards. Signiﬁcant miRs in the
different classes are shown. Values represent miR fold differences between
the groups compared with complete response. (B) Centroid analysis of the
identiﬁed miRs. Blue, down-regulated miRs; yellow, up-regulated miRs. Com-
plete response (CR), partial response (PR), stable disease (SD), and pro-
gressive disease (PD) are shown. (C) Signiﬁcant miRs in the training set
redeﬁned in two classes: nonresponder (SD and PD) and responder (CR and
PR). (D) Signiﬁcant miRs in the validation set. RQ represents fold changes in
the two groups.
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MDAH-2774-miR-484, and 17 ± 8.9 (range = 5–28) for MDAH-
2774-EGFP (P = 0.0009) (Fig. 4 A and B). Performing a Spear-
man rank correlation test and correlating miR-484 expression
values and microvessel density of the same samples, we found
a strong inverse relationship between vessel number and miR
expression (r = −0.8, P = 1.56E−07), suggesting that the sensi-
tivity of these tumors is caused by their microvessel asset driven
by miR regulation (Fig. 4A). Accordingly, the expression of
VEGFB and VEGFR2 in human tumors correlated with the
different levels of miR-484 and the response to therapy. Indeed,
responder tumors (high miR-484) showed levels of both VEGFB
and VEGFR2 signiﬁcantly lower than nonresponder tumors
(Fig. 4 C and D) as evaluated by immunohistochemistry. Among
15 responder tumors, 13 tumors expressed weak levels of VEGFB,
and 11 tumors expressed weak levels of VEGFR2 (Fig. 4 C, Right
and D, Right). Conversely, in nonresponder tumors, all but one
tumor expressed moderate/high levels of both VEGFB and
VEGFR2 (Fig. 4 C, Right and D, Right).
miR-484 Is a Secreted miR That Regulates the Expression VEGFR2 in
Tumor-Associated Endothelial Cells. Our data indicated, so far, that
miR-484 is involved in the regulation of both VEGFB and
VEGFR2 in primary ovarian cancers and xenograft tumors
formed by ovarian cancer cells (Fig. 4). Although these data
compellingly showed that miR-484 targeted VEGFB in EOC
cells, we did not observe any effects of miR-484 on VEGFR2
expression in EOC cells, mostly because all of the tested cell lines
expressed very low/undetectable levels of the receptor (Fig. 5E).
It is now well-accepted that miRs can be secreted and/or
released in the local microenvironment and into circulation,
acting as paracrine and/or endocrine regulators of several bi-
ological functions, including cancer cell growth (18). We, thus,
hypothesized that miR-484 could be released into the local mi-
croenvironment from EOC cells and penetrate into the endo-
thelial cells, thus eventually modulating its targets. To prove this
hypothesis, we ﬁrst evaluated if miR-484 could be secreted into
the conditioned medium of EOC. We evaluated the levels of
miR-484 in MDAH-2774 and SKOV-3 cells stably transduced
with scr or miR-484 lentiviral vectors in their conditioned me-
dium (CM). Normalized expression of the miR-484 revealed that
stably transduced cells showed a two- to threefold increase of its
expression over controls (Fig. 5A). Importantly, the levels of
miR-484 in the CM of SKOV-3 and MDAH-2774 exactly par-
alleled the miR levels observed in the cells (Fig. 5B), showing
that miR-484 is secreted and that the amount of miR secreted
is directly dependent on the amount of miR-484 produced by
cancer cells. Next, we asked whether the secreted miR could
penetrate into tumor-associated endothelial cells. We cocultured
human umbilical vein endothelial cells (HUVEC) and ovarian
cancer cell-derived cell lines overexpressing miR-484-EGFP or
scrambled miR-EGFP using a transwell-based assay. HUVEC
expressed low levels of miR-484, which were slightly increased
by coculture with scrambled miR-EGFP–expressing cells when
both SKOV-3 and MDAH-2274 cells were used (Fig. 5C). How-
ever, levels of miR-484 increased from one- to ﬁvefold compared
with controls in HUVEC cells cultured in the presence of
Fig. 2. miR-484 modulates in vivo response to chemotherapy. (A) Tumor volume of mice injected in the right ﬂank with MDAH-2774 control cells and injected
in the left ﬂank with MDAH-2774–overexpressing miR-484. The size of the tumors (Left) at day 0 of the CBDCA+Tax treatment and (Right) their increase after
21 d of treatment are shown. (B) In vivo imaging of nude mice injected in the right ﬂank with SKOV-3 control cells and injected in the left ﬂank with SKOV-3–
overexpressing miR-484. Images were taken (Left) immediately before the start of the treatment and (Right) after 21 d of CBDCA+Tax treatment. (C)
Quantiﬁcation of in vivo EGFP ﬂuorescence of the experiment described in B at (Left) day 0 and (Right) after 7, 14, and 21 d of treatment. (D) Effects of
intratumoral injection of lentivirus-expressing control (scr) or miR-484 in the presence of CBDCA+Tax treatment. (E) Tumor necrosis percentages in scr- and
miR-484–transduced tumors are shown. (F) H&E examples of (Left) scr-transduced tumor and (Right) miR-484. Green circles represent the tumor area, and the
yellow circle is the area of necrosis. (Scale bar: 0.5 mm.) The signiﬁcant differences are reported in each graph as evaluated by nonparametric t tests. Dif-
ferences were considered signiﬁcant when P < 0.05.






miR-484–overexpressing cell lines (Fig. 5C). In addition, the
level of mir-484 in HUVEC cells paralleled the expression of
miR-484 in cocultured endothelial cells (compare Fig. 5A with
Fig. 5C). Because the coculture was performed using a transwell-
based assay, in which cancer and endothelial cells were separated
by a porous membrane, we could exclude that a direct contact
between ovarian carcinoma cell lines and HUVEC cells was
necessary for the passage of miR-484 from cancer to endothelial
cells. Accordingly, incubating HUVEC cells for 24 h only with
the CM from miR-484–overexpressing SKOV-3 cells resulted
in a twofold increase in the levels of miR-484 compared with
controls. To further prove that miR-484 could pass from EOC to
endothelial cells when the two types of cells were cocultured, we
transfected SKOV-3 cells with a ﬂuorescently labeled miR-484
oligo; 12 h later, cells were washed, detached, and replated in
a 1:1 dilution with HUVEC and then cocultured for an addi-
tional 24 h. At this time point, cells were ﬁxed and stained with
the anti-CD31 antibody to identify the cocultured endothelial
cells. As shown in Fig. 5D, not only did all of the CD31-negative
SKOV-3 cells show the presence of labeled miR-484 in their
cytoplasm, but also, 38 ± 10% of CD31-positive endothelial cells
were positive for the ﬂuorescently labeled miR-484 (Fig. 5D).
Collectively, these data show that miR-484 produced from EOC
cells is secreted by the neoplastic cells into the local microenvi-
ronment and enters HUVEC cells within 24 h. The passage of
miR-484 from EOC to endothelial cells had functional con-
sequences: in fact, when HUVECs were cocultured with control
and miR-484–overexpressing SKOV-3 cells for 24 h, only the
latter cells were able to signiﬁcantly decrease the expression of
VEGFR2 protein on endothelial cells (Fig. 5E).
Overall, in vitro and in vivo data show that miR-484 targets
both VEGFB and VEGFR2 proteins and suggest that the ex-
pression of miR-484 in EOC cells could inﬂuence endothelial
cell growth and motility in a paracrine manner. To prove this
hypothesis, the CM from MDAH-2774 or SKOV-3 cell lines
Fig. 3. miR-484 directly targets VEGFB and VEGFR2. (A, Left) Alignment of
potential miR-484 binding sites in the 3′ UTR of VEGFB, (A, Center) expres-
sion of miR-484 in SKOV-3 ovarian cancer cells transfected either with con-
trol (scr) or miR-484, (A, Lower Right) Western blot analysis of VEGFB after
transfection of miR-484 in SKOV-3 cells, and (A, Upper Right) densitometric
ratio between the expression of tubulin and VEGFB. (B, Left) Alignment of
potential miR-484 binding sites in the 3′ UTR of VEGFR2, (B, Center) ex-
pression of miR-484 in HUVEC cells transfected with control (scr) or miR-484,
(B, Lower Right) Western blot analysis of VEGFR2 after transfection of miR-
484 in HUVEC cells, and (B, Upper Right) densitometric ratio between the
expression of tubulin and VEGFR2. (C) Luciferase assay showing decreased
luciferase activity in cells cotransfected with pGL3-VEGFB-3′ UTR or pGL3-
VEGFR2-3′ UTR and control or miR-484 oligonucleotides. Mutations in the
putative miR-484 binding sites, depicted in red in A for VEGFB and B for
VEGFR2, abrogate this effect (Mut). Bars indicate Fireﬂy luciferase activity
normalized to Renilla luciferase activity ± SD. Each reporter plasmid was
transfected in SKOV-3 cells at least two times (on different days), and each
sample was assayed in triplicate.
Fig. 4. miR-484 levels correlate with vessel density in ovarian cancer samples.
(A) Human tumors: CD34 staining (brown) of (Left) responder and (Center)
nonresponder tumors showing a higher vascular density with pronounced
microvessel formation in the latter. (Right) Regression analysis of miR-484 and
vessel number in the same samples. (B) Mouse tumors: CD34 staining (brown)
of SKOV-3 cell lines xenograft tumors transduced with (Left) miR-484 or
(Center) control (EGFP) showing a higher vascular density in the latter. (Right)
Tumor vessel count in mouse xenograft tumors transduced with control
(EGFP) or miR-484 in SKOV-3 or MDAH-2774 cells. (C) VEGFB staining in hu-
man tumors: responder tumor showing (Left) weak (intensity 1) cytoplasmic
VEGFB staining. (Center) Nonresponder tumor showing strong (intensity 3)
cytoplasmic staining of VEGFB. (Right) Case number (y axis) and intensity of
staining in the different groups (x axis). (D) VEGFR2 staining in human
tumors: responder tumor showing (Left) weak (intensity 1) cytoplasmic
VEGFR2 staining. (Center) Nonresponder tumor showing strong (intensity 3)
cytoplasmic staining of VEGFR2. (Right) Case number (y axis) and intensity of
staining in the different groups (x axis). The signiﬁcant differences are
reported in each graph as evaluated by nonparametric t tests. Differ-
ences between groups (responder vs. nonresponder) were considered
signiﬁcant when P < 0.05.
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stably transduced with miR-484 or scr-vector was used to stim-
ulate HUVEC endothelial cells in a tube formation assay on
a Matrigel matrix. Video time-lapse microscopy showed that CM,
from scr-MDAH-2774 (Movie S1) or SKOV-3 (Fig. S2) cells, was
able to induce the formation of tube-like structures when HUVEC
cells were cultured for 6 h on 3D Matrigel. This effect was im-
paired when CM from MDAH-2774– (Movie S2) or SKOV-3–
overexpressing miR-484 (Fig. S2) was used and abolished when
cells were cultured in the presence of CM for 20 h (Fig. S2).
Overall, these data conﬁrm that miR-484 expression in ovarian
cancer cells is able to affect the ability of endothelial cells to form
and sustain the formation of vascular-like structures.
Discussion
Considering the poor prognosis for patients with ovarian neo-
plasms, mainly because of late diagnosis and low response to
chemotherapy, we have attempted to identify predictive markers
of therapeutic response and molecular targets to increase sen-
sitivity to treatment. miRs, a class of gene regulators, have been
proven to be effective in classifying normal and cancerous tissues
as well as cancer prognosis. Data on ovarian cancer thus far in-
dicate that the miR network is very important to understanding
ovarian cancer biology and resistance to therapy (19, 20). Ana-
lyzing 198 samples of serous ovarian carcinoma, we discovered
that three miRs (484, 642, and 217) were capable of conferring
a responder or nonresponder status on ovarian cancer. Focusing
our attention on miR-484, we unveiled its mechanism of action
in modulating chemosensitivity through the vasculature asset. It
is interesting to note that this miR targets both VEGF signaling
pathways by either directly modulating the VEGFB protein on
the neoplastic cells or interfering with the receptor VEGFR2 in
the tumor-associated endothelial cells. The concomitant modula-
tion of the VEGFB and VEGFR2 leads to a normalization of the
tumor microenvironment through the control of new vessel for-
mation and maturation, thus improving cancer treatment (21, 22).
Several reports point to the VEGFB–VEGFR1 axis as one of
the determinants of ovarian cancer neovascularization (23, 24).
The fact that ovarian cancer cells overexpressing miR-484 are less
able to stimulate endothelial cell reorganization in vitro (Fig. S2)
and neovascularization in mice (Fig. 4) strongly supports this
hypothesis. It is also likely that the cooperation between VEGFR1
and -2 signaling is necessary for ovarian cancer growth and drug
sensitivity. Indeed, recent results showed that only the simultaneous
inhibition of VEGFR1 and -2 is able to signiﬁcantly reduce the
growth of solid human ovarian carcinoma injected i.p. in mice (25).
The importance of neoangiogenesis in ovarian cancer has been
proven in human patients, where several phase II clinical trials
with antiangiogenic compounds used as single agents to pretreat
women resulted in a 16–21% response rate (26). These trials
were instrumental for the randomized phase III studies [gyne-
cologic oncology group (GOG) 218 and ICON-7] that compared
the added use of bevacizumab with the standard i.v. agents car-
boplatin and paclitaxel. The results from GOG 218 showed an
additional 3.8 mo of progression-free survival (27), whereas the
ICON-7 study reported an increased progression-free survival of
1.7 mo (28). Interestingly, the ICON-7 study showed that the
beneﬁt of adding bevacizumab to standard chemotherapy par-
ticularly beneﬁted patients at high risk of disease progression,
supporting our hypothesis that targeting tumor neoangiogenesis
will represent a useful approach in the treatment of ovarian
cancer patients. However, adding bevacizumab to standard
treatment will not represent a cost-effective option for advanced
ovarian cancer patients (27). Furthermore, even tumors initially
responding to anti-VEGF/VEGFR2 therapy ultimately acquire
resistance to the treatment, and relapse occurs in virtually all
patients (29). Thus, although antiangiogenic therapy has proven
to be a valuable tool in cancer treatment, there is an urgent need
for alternative strategies to target the tumor vasculature and
better select the patients who will beneﬁt from antiangiogenic
compounds. Our work provides important information on both
of these aspects and will likely lead to an improved treatment for
ovarian cancer patients. In fact, we discovered that the molecular
signature of three miRs could potentially identify those patients
who will respond to conventional chemotherapy and those
patients who will effectively beneﬁt from the addition of anti-
angiogenic compounds, thereby also reducing the costs of the
therapies and improve the efﬁcacy of the drugs. Moreover, our
data strongly suggest that blockage of VEGF by the use of an
anti-VEGFA antibody alone may not be useful in ovarian cancer
patients unless VEGFB signaling is also blocked. Alternatively,
small compounds, such as functionalized nanoparticles (30) tar-
geting the VEGFR1 and -2 receptors, could be used as effective
therapy in these patients, changing the course of prognosis and
treatment of ovarian cancer.
Materials and Methods
A more detailed and complete description of all methods is provided in SI
Materials and Methods.
Patients. After Institutional Review Board approval (ethical committees of
CRO AVIANO, Santo Andrea Hospital and National Cancer Institute, Naples),
we obtained 198 specimens of naïve invasive serous carcinoma of the ovary.
Data on clinical outcome were obtained from patients’ records (Table S1).
Response to initial chemotherapy was classiﬁed according to the response
evaluation criteria in solid tumors (RECIST) guideline as complete response,
partial response, stable disease, and progressive disease (31). We randomly
divided 198 specimens into a training set of 86 samples and a validation set
of 112 samples. All samples were chosen by four pathologists (A.V., S.L., V.C.
and A.S.) to minimize the amount of normal tissues (<5%). Where normal
tissue exceeded the limitation, we performed laser microdissection of the
samples according to standard procedures.
miR Expression Proﬁling and Data Validation. miR expression proﬁling was
performed on the training set (86 samples) using TaqMan Array Human
MicroRNA Set v2.0 containing a total of 676 unique assays. Differentially
expressed miRs were validated on the validation set (112 samples) using the
TaqMan MicroRNA assay.
Data Analysis. TaqMan Low-Density Array (TLDA) cards and RT-PCR data
were analyzed using the comparative CT (ΔΔCT) method (32) for relative
Fig. 5. miR-484 is secreted by ovarian cancer cells and targets VEGFR2 in
endothelial cells. (A and B) Expression of miR-484 in (A) ovarian cancer cells
and (B) their conditioned mediums in cells stably transduced with control or
miR-484 vectors. (C) Levels of miR-484 in HUVEC cells cocultured with
ovarian cancer-derived cell lines. (D) Confocal microscopy image of cocul-
tured SKOV-3 cells transfected with miR-484–ﬂuorescin-conjugated (green)
and HUVEC stained with CD31 antibody–Texas Red-conjugated (red). (E,
Left) Western blot analysis of VEGFR2 expression in HUVEC cells cultured in
CM from SKOV-3 cells stable transfected with miR-484 or EGFP. (E, Right)
Densitometric ratio between the expression of tubulin, and VEGFR2. The
signiﬁcant differences are reported in each graph as evaluated by non-
parametric t tests. Differences were considered signiﬁcant when P < 0.05.






quantiﬁcation of gene expression on Data Assist ver.1.2 (Applied Biosystems).
For each sample, the mean miR expression value was calculated as the av-
erage of Ct values smaller than 35. Samples were labeled based on either
their response to ﬁrst chemotherapy or other clinical parameters. We used
the one-way ANOVA test to identify differentially expressed miR using R
software. Global median normalization was used for the expression analysis
of the TLDA cards. miR-16 and -191, both among the most invariable miRs in
the training set, were used as endogenous controls for normalization of the
RT-PCR in the validation set. All data were expressed as the mean ± SEM.
Statistically signiﬁcant differences between nonresponders and responders
(control) were determined using the nonpaired Student two-tailed t test. A
value of P < 0.05 was considered statistically signiﬁcant. Centroid analysis was
performed using Cluster combined with Java TreeView for graphical output.
Microarray data have been submitted to the Gene Expression Omnibus (ac-
cession no. GSE43867).
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